Weight‑loss pills arrive
Regulators approved a new oral GLP‑1 weight‑loss pill called Foundayo in April, marking a shift toward pill options people want for convenience and cost. (The Motley Fool: ) New guidance from three obesity associations lays out specific recommendations for these drugs and explicitly calls for steps to reduce stigma, even as AI analysis of Reddit posts flagged possible new side effects to watch. (Medscape: ) (Medical News Today: ) Doctors in India are already warning against rushed pre‑wedding injection use — the so‑called “Mounjaro brides” trend — because of safety and long‑term concerns. (Hindustan Times: )
A new weight-loss pill reached the United States market on April 1, giving patients a once-daily alternative to injectable glucagon-like peptide-1 drugs. (fda.gov) The Food and Drug Administration approved Foundayo, the brand name for orforglipron, for adults with obesity or adults with overweight plus at least one weight-related condition. The agency said the tablet should be used with a reduced-calorie diet and more physical activity. (fda.gov) Glucagon-like peptide-1 drugs copy a gut hormone that helps people feel fuller and eat less. Foundayo is a tablet taken once a day, and the Food and Drug Administration said it does not need to be taken on an empty stomach. (fda.gov) The approval moved unusually fast. The Food and Drug Administration said it issued the decision 50 days after filing, 294 days before the January 20, 2027 user-fee deadline, under its Commissioner’s National Priority Voucher pilot program. (fda.gov) Doctors are also getting new instructions on how to use these medicines. A joint guidance statement published March 5 by The Obesity Society, the Obesity Medicine Association, and the Obesity Action Coalition said obesity affects more than 40% of United States adults and remains underdiagnosed and undertreated. (pubmed.ncbi.nlm.nih.gov) That guidance reviewed Food and Drug Administration-approved obesity drugs including orlistat, bupropion-naltrexone, phentermine, phentermine-topiramate, liraglutide, semaglutide, tirzepatide, and setmelanotide. The abstract said the panel weighed benefits, harms, equity, and feasibility using the Grading of Recommendations Assessment, Development and Evaluation approach. (pubmed.ncbi.nlm.nih.gov) Researchers are also looking for side effects outside clinical trials. University of Pennsylvania researchers said on April 10 that an artificial intelligence review of more than 400,000 Reddit posts from nearly 70,000 users found patient-reported symptoms tied to semaglutide and tirzepatide that may not be fully captured in labels or trial reports. (seas.upenn.edu) Medical News Today said the study flagged reports involving menstrual changes and body-temperature symptoms such as chills and hot flashes. The outlet said the findings point to signals for follow-up, not proof that the drugs caused every reported symptom. (medicalnewstoday.com) In India, demand is already outrunning caution in some clinics. Reuters reported on April 3 that wellness centers were marketing “Mounjaro bride” packages to people trying to lose weight before weddings. (usnews.com) Eight doctors interviewed by Reuters said they were fielding inquiries from brides and some grooms about taking the drugs before their ceremonies, and doctors warned against using them as short-term cosmetic shortcuts. As pills arrive and access widens, the medical advice is getting more specific, not less. (indianexpress.com)
